Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

Inclusion Criteria

• •Patients with squamous cell carcinomas of the oropharynx, larynx and oral cavity for whom definitive or postoperative chemoradiation is indicated
• •Patients who are cisplatin-unfit for chemotherapy, defined as:
• •* ECOG 2
• •* Organ dysfunction ≥ 2 according to National Cancer Institute Common Toxicity Criteria (NCI CTC) Version 4.0, such as hearing loss or tinnitus or neurological diseases
• •* Calculated creatinine clearance of ≤50ml/min
• •* Impaired organ function or comorbidities that preclude the use of cisplatin, e.g.: left ventricular ejection fraction \< 50%, uncorrectable renal insufficiency with elevated creatinine despite creatinine clearance of 50ml/min due to increased body weight, uncontrolled hypertension
• •* Poor nutritional status BMI \< 16kg/m²
• •* Concomitant use of nephrotoxic drugs that cannot be discontinued or converted due to other illnesses.
• •* Willingness of patients to provide blood, saliva and stool samples and consent to the preservation of all samples for study purposes
• •* Age ≥ 18 years
• •* Sufficient cognitive abilities of the patients to understand the purpose of the study and to consent to it